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Cell-free microRNAs have been reported as biomarkers for several diseases. For
testicular germ cell tumors (GCT), circulating microRNAs 371a-3p and 372-3p in serum
and plasma have been proposed as biomarkers for diagnostic and disease monitoring
purposes. The most widely used method for quantification of specific microRNAs in
serum and plasma is reverse transcriptase real-time quantitative PCR (RT-qPCR) by the
comparative Ct-method. In this method one or several reference genes or reference
microRNAs are needed in order to normalize and calculate the relative microRNA
levels across samples. One of the pitfalls in analysis of microRNAs from serum and
plasma is the release of microRNAs from blood cells during hemolysis. This is an
important issue because varying degrees of hemolysis are not uncommon in routine
blood sampling. Thus, hemolysis must be taken into consideration when working with
circulating microRNAs from blood. miR-93-5p, miR-30b-5p, and miR-20a-5p have been
reported as reference microRNA in analysis of the miR-371a-373 cluster. We here
show how these three microRNAs are influenced by hemolysis. We also propose a
new reference microRNA, miR-191-5p, which is relatively stable in serum samples with
mild hemolysis. In addition, we show how hemolysis can have effect on the reported
microRNA levels in patient samples when these reference microRNAs are used in
samples with varying levels of hemolysis.
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INTRODUCTION
MicroRNAs of the miR-371-373 cluster, which are produced in embryonal tumors, have been
proposed as sensitive biomarkers for testicular germ cell tumors (GCT), both in primary cases and
recurrences (Suh et al., 2004; Belge et al., 2012; Dieckmann et al., 2012; Gillis et al., 2013; Syring
et al., 2015; Murray et al., 2016; Anheuser et al., 2017; Terbuch et al., 2018; Dieckmann et al., 2019).
miR-371a-3p, which has the highest sensitivity and specificity of these miRNAs, has been shown
to be expressed in both seminomas and non-seminomas, except pure teratomas (Dieckmann et al.,
2016; Vilela-Salgueiro et al., 2018). Dieckmann et al. (2017) reported miR-371a-3p to detect GCT
with sensitivity and specificity of 88.7 and 93.4%, respectively.
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Detection of specific, free, circulating microRNAs in serum
and plasma as biomarkers is warranted as it is a simple,
non-invasive technique with little discomfort for the patient.
In addition, medical staff, both in hospitals and primary health
care, are trained to draw and handle blood samples. MicroRNAs
have been shown to be stable in whole blood and separated
serum and plasma for several hours (Mitchell et al., 2008; Glinge
et al., 2017). Standard tubes and centrifugation protocols for
plasma and serum collection can be used, and separated serum
and plasma can be frozen for later analysis. Detection and
relative quantification can be performed by real-time quantitative
PCR which is well-established in molecular hospital laboratories.
MicroRNAs have also been shown to have short half-life and
rapid decay in circulation (Radtke et al., 2018). These features
make circulating microRNA suitable as biomarkers, but still
there are challenges and pitfalls. MicroRNAs are present in
varying amounts in every cell of the body, including blood cells.
Lysis of blood cells during phlebotomy or sample handling can
therefore yield false high levels of miRNAs not reflecting the
actual levels in circulation.
The minute amounts of specific microRNAs in serum and
plasma need very sensitive methods for detection. Relative
quantitation of microRNAs by reverse transcription real-time
PCR (RT-qPCR) needs at least one reference gene in order to
normalize samples, most preferably an endogenous microRNA
(reference microRNA). Reference microRNAs must be expressed
at similar levels throughout all samples tested, both in serum
or plasma from individuals with the disease in question and
in healthy controls. However, suitable reference microRNAs
are often expressed at high levels in blood cells. Thus, the
quantification is prone to error due to increased levels of the
reference microRNA(s) caused by rupture of blood cells. Thus,
hemolysis must be taken into account if the endogenous controls
used are expressed in blood cells (Murray et al., 2016; Poel
et al., 2018). Pre-analytical steps must be considered carefully
and standardized in sampling and handling of the blood samples
(Marzi et al., 2016; Pizzamiglio et al., 2017; Murray et al., 2018).
There are several methods for assessment of hemolysis in serum
and plasma, e.g., the ratio between miR-451 and miR-23 (Blondal
et al., 2013), or absorbance at 414 nm (Kirschner et al., 2013;
Shah et al., 2016).
Here we show how hemolysis affects four microRNAs used as
reference genes in the quantitative analysis of miR-371a-3p and
miR-372-3p. miR-93-5p, miR-20a-5p, and miR-30b-5p have been
used as reference genes in analysis of the miR-371-373 cluster
in serum (Gillis et al., 2013; Murray et al., 2016; Dieckmann
et al., 2017). In addition, we propose a new reference microRNA,
miR-191-5p. Further, we demonstrate how hemolysis will affect
the calculated relative quantity (RQ) of miR-371a -3p and
miR-372-3p in patient samples.
MATERIALS AND METHODS
Blood Samples
In this study, we analyzed serum samples from two patients
diagnosed with testicular germ cell cancer, Patient 1 and Patient 2.
The blood was collected prior to orchiectomy in 10 mL BD
Vacutainer vials with clot activator. After coagulation, serum was
separated from the blood cells by centrifugation at 2000 × g
for 10 min at 20◦C within 1 h, aliquoted and frozen at –80◦C.
Absorbance at 414 nm was measured to assess baseline hemolysis
in the serum samples. Red blood cells (RBCs) were collected
from a healthy donor by centrifugation of 3 mL K2EDTA whole
blood, with removal of plasma and buffy coat. The RBC fraction
was hemolyzed by sonication. Serum was collected from the
same individual and processed as described for the patient
samples for use in the preparation of hemolysis standard curves
described below.
No, weak and medium hemolysis in aliquots of the patient’s
serum samples were imitated by adding RBC lysate to 0.0%
(v/v, No hemolysis), 0.05% (Weak hemolysis) and 0.2% (Strong
hemolysis) (v/v). Five replicates for each sample and hemolysis
condition were performed.
Hemolysis Serial Dilutions
Hemolysis was assessed by absorbance at 414 nm (A414)
(Kirschner et al., 2013) in all the spiked and non-spiked
serum samples using a NanoDrop 2000 spectrophotometer
(NanoDrop Products). All absorbance measurements were
performed in triplicates.
Standard curves for absorbance assessment of hemolyzed
serum samples were made by serial dilutions of hemolyzed
RBCs in serum from a healthy individual. The samples ranged
from 0.0 to 1.0% (v/v) hemolysate. A414 was recorded prior
to RNA extraction from these serum samples and followed by
RT-qPCR for miR-93-5p, miR-30b-5p, miR-20a-5p, and miR-
191-5p as described for the patient samples, except omission of
the pre-amplification step. The experiment was repeated trice.
The raw Cq-values were used to visualize how the levels of
the four microRNAs increased with increasing concentration of
hemolyzed RBCs in serum.
RNA Extraction and RT-qPCR
TotalRNA including small RNAs was extracted from all samples
using the miRNeasy kit (Qiagen P/N 217004, protocol RY43).
A standard volume of 200 µL serum was added to 1 mL Qiazol
Lysis Reagent. A mix of synthetic spike-in UniSp4 (RNA Spike-
in kit, 339390, Qiagen) and 3 µg glycogen (R0551, Thermo
Fisher Scientific) as carrier was added to the homogenate prior
to phase-separation by chloroform. A standard volume of 500 µL
upper phase was extracted and further processed as described
by the manufacturer. RNA was eluted in 30 µL nuclease-
free water.
Template RNA, at a fixed amount of 2 µL in each reaction,
was reverse transcribed into cDNA using the Universal cDNA
Synthesis kit II (Qiagen, PN 203301). In order to monitor the
cDNA synthesis step, the synthetic cel-miR-39-3p (RNA Spike-
in kit, Qiagen PN 339390) was included in the reaction mix
of the cDNA synthesis. The final reaction mix of 10 µL was
then incubated in a thermocycler at 42◦C for 60 min and 95◦C
for 5 min. Five cDNA replicas were made for each sample
and each hemolysis condition. Due to the low levels of miR-
371a-372 in serum, a pre-amplification step was performed for
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TABLE 1 | Assays used in pre-amplification and qPCR of microRNAs.









the patient samples (Murray et al., 2011). A primer pool was
assembled with the forward and reverse primers for hsa-miR-
371a-3p, hsa-miR- 372-3p, miR-20a-5p, miR-30b-5p, hsa-miR-
93-5p, hsa-miR-191-5p, UniSp4 and cel-miR-39-3p (all assays
were miRCURY LNA miRNA PCR Assays from Qiagen, Table 1)
with each assay at a final concentration of 0.1×. The reaction mix
consisted of 2.5 µL 5× PerfeCTa PreAmp SuperMix (Quantabio,
PN 95146), 3.125 µL primer pool, 3.1 µL cDNA (diluted 1:40)
and nuclease-free water to a total volume of 12.5 µL. The pre-
amplification was performed in a thermocycler with denaturation
at 95◦C for 10 min followed by 14 cycles of 95◦C for 15 s and
60◦C for 4 min. The pre-amplification product was diluted 1:5
in nuclease-free water and taken into qPCR in single assays.
The qPCR reaction mix contained 5 µL 2× PerfeCTa SYBR
Green Supermix (Quantabio, PN 95054), 1 µL of the respective
miRCURY LNA miRNA PCR Assay (Qiagen, Table 1) and
4 µL diluted pre-amp product. The qPCR was carried out in
triplicates in 384 well plates on a LightCycler480 instrument.
Cycling conditions were 95◦C for 10 min, 45 cycles of 95◦C
for 10 s and 60◦C for 1 min. Melting curve analysis was
performed for each well. Pipetting in qPCR was performed by
robotics using a BioMek 3000 Laboratory Automation Station
(Beckman Coulter).
Quantification of MicroRNAs
The microRNAs were quantified using the comparative
Ct-method (Schmittgen and Livak, 2008).
11Cq (miRi) = (Cq samplemiRi − Cq samplemiRref)
− (Cq calmiRi − Cq calmiRref)
where miRi = microRNA of interest, miRref = reference miR,
sample = patient sample and cal = calibrator sample.
The calibrator sample was a patient sample with very low levels
of miR-371a-3p and miR-372-3p. RQs are 2−11Cq.
Statistical Tests and Ethics
The study was approved by the Regional Ethics Committee of
Central Norway (REK Midt, 2015/1475). Patients included in
the study gave written informed consent in accordance with
the Declaration of Helsinki. All statistical tests were performed
in IBM SPSS Statistics Version 25. Expression levels of the
microRNAs were compared using the Student’s t-test with
Levene’s F-test for equality of variances. P-values < 0.05 in the
two tailed t-tests were considered significant.
RESULTS
Hemolysis and Reference MicroRNAs’
Levels
The serial dilution of hemolyzed RBCs in serum showed that
the amounts of RBCs added ranged from a non-detectable to
a strong red color by visual inspection (Figure 1A). By eye,
hemolysis could be detected at approximately 0.06% (v/v) RBCs
in blood, but the hemolysis did not appear pronounced until
0.25% (v/v). The absorbance measurement at 414 nm showed a
linear absorbance increase in the analyzed range (0–1.0% v/v)
RBCs in serum (Figures 1B,C).
Quantification by RT-qPCR of the miRNAs proposed as
endogenous controls in analysis of microRNAs 371a-372 in
serum showed that the concentration of miR-191-5p and miR-
30b-5p did increase in serum when hemolysis occurs, but the
increase in miR-93-5p and miR-20a-5p were more pronounced
(Figure 2). According to the Cq-values shown in Figure 2,
the levels of miR-93-5p and miR-20a-5p increased in serum
from the lowest amount of 0.008% added RBCs. The increase
in miR-93-5p and miR-20a-5p appeared almost linear. There
was a small increase in miR-191-5p and miR-30b-5p in serum
when 0.008% hemolyzed RBCs were added, but the raw Cqs
were quite stable until 0.125% RBCs were added. Hence,
according to our results miR-191-5p and miR-30b-5p were
the microRNAs that were the least influenced by hemolysis
among the four microRNAs tested. miR-93-5p and miR-20a-5,
on the other hand, are abundant in blood cells and even
very weak hemolysis cause a measurable increase of these
microRNAs in serum.
Hemolysis and miR-371a- 372 Levels in
Patient Samples
Raw Cq-values from RT-qPCR analysis of miR-30b-5p, miR-
93-5p, miR-191-5p, miR-371a-3p, and miR-372-3p adjusted for
variation in RNA extraction efficiencies according to UniSp4
are shown in Supplementary Figure S1. Some variation was
seen in the RNA extraction efficiency (UniSp4, CV 3.99%),
while the cDNA synthesis step was stable (cel-miR-39-3p, CV
1.69%) across samples.
As described, two different patient samples were spiked with
increasing amounts of hemolyzed RBCs. We measured the initial
absorbance at 414 nm for the patient samples and again after
spiking (Table 2). The RBC fraction used to spike samples did
not contain any miR-371a-3p or miR-372-3p (Cq > 40, results
not shown). miR-371a-372 levels were higher in Patient 1 than
in Patient 2 (Figure 3). All RQs with 95% confidence intervals
(95% CI) are available in Supplementary Table S1. The miR-
371a-3p and miR-372-3p RQs for Patient 1 and Patient 2 are
statistically significant lower in the spiked samples than in the
sample with no added RBCs. As shown in Figures 3A,D,G,J,
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FIGURE 1 | Visual inspection and absorbance measurement of hemolyzed red blood cells in serum. (A) Serum with low initial absorbance at 414 nm was spiked
with varying amounts of hemolyzed RBCs. The percentage indicated is v/v. (B) Absorbance at 414 nm for the different concentrations of hemolyzed RBCs in serum.
The three replicates for each concentration are plotted. (C) A414 at different RBC-concentrations (%, v/v) in serum.
the RQs of both miR-371a-3p and miR-372-3p were statistically
significant lower in the samples with added RBCs than in the
sample with no added RBCs when miR-93-5p was used as
FIGURE 2 | Raw Cq-values of endogenous miR-191-5p, miR-93-5p,
miR-30b-5p, and miR20a-5p in serum spiked with hemolyzed RBCs. Values
shown are mean Cq-values with SD from the three replicates. Raw Cq-values
were adjusted according to UniSp4 in order to correct for variations in RNA
extraction efficiency.
endogenous control (P < 0.05). The differences in RQs between
the “Weak” and “Strong”-hemolysis samples are also statistically
significant lower (P < 0.05). When miR-30b-5p was used as
endogenous control in these samples, the differences in RQs in
“No hemolysis” versus “Weak hemolysis” were lower, but still
statistically significant for miR-371a-3p in both Patient 1 and
Patient 2 (Figures 3B,H, P = 0.036 and P = 0.011, respectively)
and for miR-372-3p in Patient 2 (Figure 3E, P = 0.010), but
not significant for Patient 1 (Figure 3K, P = 0.112). miR-191-5p
as reference microRNA gave miR-371a-5p and miR-372-5p RQs
that were not statistically significant higher in the “No hemolysis”
versus the “Weak hemolysis” samples (P > 0.05, Figures 3C,F,L),
except for miR-371a-3p in Patient 2 (Figure 3I, P = 0.023).
Regarding the differences in RQ for both miR-371a-3p and
miR-372-3p between “No hemolysis” and “Strong hemolysis,”
TABLE 2 | Absorbance at 414 nm in patients’ serum before and after
spiking with RBCs.
No added RBCs 0.05% RBC added: 0.2% RBCs added
Sample (no hemolysis) (weak hemolysis) (strong hemolysis)
Patient 1 0.148 0.222 0.330
Patient 2 0.120 0.154 0.292
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FIGURE 3 | Hemolysis affected the measured levels of specific microRNAs in serum from the two patients, Patient 1 and Patient 2. Relative quantities (RQs)
representing miR-371a-3p and miR-372-3p were calculated with miR-93-5p (A,D,G,J), miR-30b-5p (B,E,H,K) and miR-191-5p (C,F,I,L) as reference genes. “No,”
“Weak,” and “Strong” represent the same serum, but with 0.0, 0.05, or 0.2% added RBCs, respectively. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Bars represent mean
RQ with standard deviations (SD). RQ = 2−11Cq.
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FIGURE 4 | Hemolysis affected the measured levels of specific microRNAs in
serum from the two patients. Relative quantities (RQs) representing
miR-371a-3p and miR-372-3p in Patient 1 and Patient 2 were calculated with
the average of miR-191-5p and miR-30b-5p (A–D) or the average of
miR-30b-5p and miR-93-5p (E–H) as reference genes. “No,” “Weak,” and
“Strong” represent the same serum, but with 0.0, 0.05, or 0.2% added RBCs,
respectively. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Bars represent mean RQ
with standard deviations (SD). RQ = 2−11Cq.
they were statistically significant in all samples for all the tested
reference microRNAs (Figures 3A–L, P < 0.05). It is generally
accepted that the mean of at least two reference genes should
be used in relative quantification of microRNAs. We therefore
calculated the RQs for miR-371a-3p and miR-372-3p with the
average of the two best reference microRNAs, miR-30b-5p and
miR-191-5p (Figures 4A–D). As expected, the results were in line
with the results for miR-30b-5p and miR-191-5p used as reference
genes alone. The differences in RQs between “No hemolysis” and
“Weak hemolysis” were smaller than when miR-30b-5p and miR-
93-5p were used in the analysis of miR-371a-372 (Figures 4E–H).
DISCUSSION
miR-371a-3p, miR-372-3p, and miR-373-3p are promising
biomarkers for detection and surveillance in testicular germ
cell cancer. miR-371a-3p in particular has been shown to
have high sensitivity and specificity (Gillis et al., 2013;
Anheuser et al., 2017; Dieckmann et al., 2017; van Agthoven
et al., 2017; Radtke et al., 2018). We have here shown how
hemolysis can have impact on quantification of microRNAs in
serum and the possible influence on clinical decisions if not
interpreted correctly.
Circulating miRNAs are interesting as biomarkers because the
sampling is easily standardized and no invasive interventions
are needed. The most used laboratory technique for targeted
detection and quantification of low numbers of microRNAs
is relative quantification by RT-qPCR (Schmittgen and Livak,
2008). Consensus is that in order to achieve robust and
reproducible relative quantification of mRNAs and microRNAs,
normalization against at least two endogenous reference miRNAs
expressed at stable levels across the samples in question should
be used to correct for variations in sample composition,
non-endogenous variation expression introduced during RNA
extraction, RNA handling and storage and the RT-qPCR protocol
(Bustin et al., 2009). The challenge in analysis of circulating
microRNAs is to identify such stably expressed endogenous
reference genes. Most of the microRNAs present at relatively
high levels in serum and plasma are also present in blood
cells and will be released to serum and plasma during cell
lysis. When working with serum and plasma from blood
samples, contamination with RBCs, WBCs or platelets can
therefore introduce variation and possibly false conclusions.
Weak hemolysis of RBC in vitro during blood sampling
are relatively common. We have in this work shown how
hemolysis even in the sub-visible range can lead to large
differences in measured miR-371a-3p and miR-372-5p levels,
even though the levels of these two microRNAs themselves are
not influenced by hemolysis.
There is an ongoing debate on how to normalize the
expression of the microRNAs in question during calculation of
RQ using the 11Ct-method. Three main strategies have been
proposed, i.e., normalization to geometric mean (Vandesompele
et al., 2002), normalization to exogenic reference miRNA e.g.,
cel-miR-39-5p (Xu et al., 2014) and normalization to stably
expressed internal reference microRNAs (Bustin et al., 2009).
Normalization to the geometric mean applies to studies analyzing
high numbers of miRNA targets e.g., miRNA sequencing or
arrays and is not suitable to studies where only a few miRNAs
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are analyzed. Levels of exogenic reference miRNAs added
to serum prior to RNA extraction will not be changed by
hemolysis, but this method is prone to pipetting variation and
batch variations and will not correct for biological variation
in overall microRNA levels in the samples. Quantification of
microRNA using the standard curve method in RT-qPCR is
not commonly used due to the challenges in concentration
measurement of the small RNAs. We find in our study
that miR-191-5p alone is the best reference microRNA. Our
study is focused on hemolysis and miR-191-5p levels in
serum may be influenced by other physiological conditions
not studied by us. In addition, this microRNA is highly
abundant in serum and might not be the best reference
microRNA when studying microRNAs expressed at very low
levels in serum.
Other groups have also argued that hemolysis must be
monitored when working with quantitative microRNA analysis
in serum or plasma (Blondal et al., 2013; Murray et al.,
2016). Different assays for hemolysis assessment are used,
e.g., the miR-451a-miR-23a-3p ratio (Blondal et al., 2013),
hemoglobin concentration measurement (Shah et al., 2016),
absorbance at 414 nm (Kirschner et al., 2013). We chose
to use absorbance measurement at 414 nm (A414) in our
study because the assessment is very cost effective, requires
minimal amounts of serum and can be performed without
further sample processing, e.g., sample quality can be assessed
prior to RNA extraction. We also based our choice of A414
as the preferred method for hemolysis detection on the
finding of Shah et al where A414 detects hemolysis down to
0.004% and correlates well with the miR-451a/23a ratio (Shah
et al., 2016). Our results clearly show that hemolysis must
be taken into consideration when working with microRNAs
in serum and plasma. Contamination of the sample with
blood cells containing any of the microRNAs analyzed can
interfere with the results, even if the hemolysis is mild
and the microRNA that increase due to hemolysis is not
the main microRNA in question, but used as a reference
microRNA in calculation of RQ. Of note, hemoglobin is
also a known inhibitor in PCR, but the concentrations of
hemoglobin must be higher than in our study to cause
inhibition (Al-Soud and Radstrom, 2001; Sidstedt et al., 2018).
In our case where the microRNAs increased by hemolysis
were not the main microRNA analyzed, but used as reference
microRNA in normalization during relative quantification by
RT-qPCR, the result will be a falsely low RQ calculated for
the miRNA in question, here miR-371a-3p and miR-372-3p.
Hypothetically as a worst case scenario, a patient sample
expressing low, but clearly true positive levels of miR-371a-
3p, could by barely visible hemolysis be concluded to have
miR-371a-3p within the normal reference range and thus
reported as non-pathological. Another hypothetical case is that
during monitoring disease activity, the conclusion based on
a hemolyzed sample could be decline in miR-371a-3p after
treatment and thus effect of treatment. The conclusion based
on the true, unchanged miR-371a-3p value would have been no
effect of treatment.
Analysis of cell-free microRNAs can be performed by other
quantitative techniques than RT-qPCR, e.g., Next Generation
Sequencing (NGS) and digital droplet PCR (ddPCR). Especially
ddPCR holds great promise in analysis of rare targets with
better precision and reproducibility, but equivalent sensitivity
compared to RT-qPCR (Hindson et al., 2013). DdPCR is an
endpoint analysis with partition through dilution and is thus less
prone to inhibitors compared to RT-qPCR (Dingle et al., 2013).
Another advantage of ddPCR is that the technique provides
absolute quantification without a calibration curve or calibrator
sample (as used in RQ). Some also argue that the endogenous
control(s) can be omitted in microRNA quantification using
ddPCR or NGS, but we argue that appropriate endogenous
controls must be used in order to correct for non-biological
variation among study samples e.g., differences in RNA
extraction efficiencies and possible degradation of samples
during storage, as is also proposed by others (Stein et al.,
2017). Using ddPCR for analysis of miR-371-373 by NGS
or ddPCR may improve the technical performance of the
microRNA detection, but hemolysis must still be accounted
for as long as microRNAs present in the RBCs are used as
endogenous controls.
To conclude, hemolysis assessment is an important
quality control when working with circulating microRNAs
in serum and plasma. Visual inspection is not sufficiently
sensitive for monitoring hemolysis. Further efforts for
finding good reference genes and normalization strategies
in RT-qPCR analysis of circulating microRNAs must go
on until consensus is reached if these microRNAs are
to be used quantitatively for diagnostic purposes and
clinical decisions.
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